Download PDF
Pharmacopsychiatry 2022; 55(06): 281-289
DOI: 10.1055/a-1804-6211
Original Paper

Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study

Andrea Aguglia   *
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Laura Fusar-Poli   *
3   Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy
,
Antimo Natale
3   Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy
,
Andrea Amerio
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Irene Espa
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Veronica Villa
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Giovanni Martinotti
4   Department of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University of Chieti, Chieti, Italy
,
Giuseppe Carrà
5   Department of Medicine and Surgery, University of Milano-Bicocca, via Cadore, Monza, Italy
6   Division of Psychiatry, University College London, Tottenham Court Rd, Bloomsbury, London, United Kingdom
,
Francesco Bartoli
5   Department of Medicine and Surgery, University of Milano-Bicocca, via Cadore, Monza, Italy
,
Armando D’Agostino
7   Department of Health Sciences, University of Milan, Ospedale San Paolo, Blocco A, Via Antonio di Rudinì, Milan, Italy
,
Gianluca Serafini
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Mario Amore
1   Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy
2   IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Eugenio Aguglia
3   Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy
,
Giovanni Ostuzzi
8   WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy
,
Corrado Barbui
8   WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Long-acting injectable (LAI) antipsychotics are prescribed to people with severe psychiatric disorders who show poor adherence to oral medication. The present paper examined factors potentially associated with medication adherence to LAI treatment.

Methods The STAR (Servizi Territoriali Associati per la Ricerca) Network Depot Study was a multicenter, observational, prospective study that enrolled 461 subjects initiating a LAI from 32 Italian centers. After 6 and 12 months of treatment, we evaluated differences between participants with high (≥5 points) and low (<5 points) medication adherence using Kemp’s 7-point scale in sociodemographic, clinical, psychopathological, and drug-related variables. Factors that differed significantly between the two groups were entered for multivariate logistic regression.

Results Six months after enrollment, participants with high medication adherence were younger, living with other people, had lower Brief Psychiatric Rating Scale (BPRS) total scores, lower adverse events, and a more positive attitude toward medication than participants with low adherence. Multivariate regression confirmed lower BPRS resistance and activation scores, absence of adverse events, and positive attitude toward medication as factors significantly associated with good adherence. After 12 months, all BPRS subscales were significantly lower in the high adherence group, which also showed a more positive attitude toward medication. BPRS resistance and attitude toward medication were confirmed as factors associated with medication adherence.

Discussion Our findings suggest that adherence to LAI is principally related to attitude toward medication and traits of suspiciousness/hostility. Quality of patient-clinician relationship and tailored psychoeducational strategies may positively affect adherence in people undergoing psychopharmacological treatment, including LAI.

Key words

long-acting injectable - antipsychotics - adherence - schizophrenia - bipolar disorder

* Shared first-authors




Publication History

Received: 08 February 2022
Received: 14 March 2022

Accepted: 16 March 2022

Article published online:
25 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Haynes RB. Compliance in health care. Baltimore, MD: Johns Hopkins University Press; 1979
    Google Scholar
  • 2 Myers LB, Midence K. Adherence to treatment in medical condition. Amsterdam: Harwood Academic Publisher; 1998
    Google Scholar
  • 3 Chakrabarti S. What’s in a name? Compliance, adherence and concordance in chronic psychiatric disorders. World J Psychiatry 2014; 4: 30-36
    CrossrefPubMedGoogle Scholar
  • 4 Fiorillo A, Barlati S, Bellomo A. et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review. Ann Gen Psychiatry 2020; 19: 43
    CrossrefPubMedGoogle Scholar
  • 5 Pacchiarotti I, Tiihonen J, Kotzalidis GD. et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol 2019; 29: 457-470
    CrossrefPubMedGoogle Scholar
  • 6 Velligan DI, Sajatovic M, Hatch A. et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 2017; 11: 449-468
    CrossrefPubMedGoogle Scholar
  • 7 Marazziti D, Mucci F, Avella MT. et al. The increasing challenge of the possible impact of ethnicity on psychopharmacology. CNS Spectr 2021; 26: 222-231
    CrossrefPubMedGoogle Scholar
  • 8 Fleck DE, Keck PE, Corey KB. et al. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry 2005; 66: 646-652
    CrossrefPubMedGoogle Scholar
  • 9 Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-226
    CrossrefPubMedGoogle Scholar
  • 10 Kretchy IA, Osafo J, Agyemang SA. et al. Psychological burden and caregiver-reported non-adherence to psychotropic medications among patients with schizophrenia. Psychiatry Res 2018; 259: 289-294
    CrossrefPubMedGoogle Scholar
  • 11 Yatham LN, Kennedy SH, Parikh SV. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170
    CrossrefPubMedGoogle Scholar
  • 12 Benkert O, Graf-Morgenstern M, Hillert A. et al. Public opinion on psychotropic drugs: An analysis of the factors influencing acceptance or rejection. J Nerv Ment Dis 1997; 185: 151-158
    CrossrefPubMedGoogle Scholar
  • 13 Helbling J, Ajdacic-Gross V, Lauber C. et al. Attitudes to antipsychotic drugs and their side effects: A comparison between general practitioners and the general population. BMC Psychiatry 2006; 6: 42 DOI: 10.1186/1471-244X-6-42.
    CrossrefPubMedGoogle Scholar
  • 14 Sajatovic M, Jenkins JH. Is antipsychotic medication stigmatizing for people with mental illness?. Int Rev Psychiatry 2007; 19: 107-112
    CrossrefPubMedGoogle Scholar
  • 15 Janssen B, Gaebel W, Haerter M. et al. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 2006; 187: 229-236
    CrossrefPubMedGoogle Scholar
  • 16 Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: A comprehensive review. J Affect Disord 2013; 149: 247-252
    CrossrefPubMedGoogle Scholar
  • 17 El-Missiry A, Elbatrawy A, El Missiry M. et al. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. J Psychiatr Res 2015; 70: 106-112
    CrossrefPubMedGoogle Scholar
  • 18 Foglia E, Schoeler T, Klamerus E. et al. Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analysis. Psychol Med 2017; 47: 1691-1705
    CrossrefPubMedGoogle Scholar
  • 19 El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: A systematic review on risk Factors and interventions for treatment adherence in psychosis. Front Neurosci 2020; 14: 531763
    CrossrefPubMedGoogle Scholar
  • 20 Dibonaventura M, Gabriel S, Dupclay L. et al. A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012; 12: 20 DOI: 10.1186/1471-244X-12-20.
    CrossrefPubMedGoogle Scholar
  • 21 Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014; 16: 505-524
    CrossrefPubMedGoogle Scholar
  • 22 García S, Martínez-Cengotitabengoa M, López-Zurbano S. et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol 2016; 36: 355-371
    CrossrefPubMedGoogle Scholar
  • 23 Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
    CrossrefPubMedGoogle Scholar
  • 24 McCann TV, Boardman G, Clark E. et al. Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 2008; 15: 622-629
    CrossrefPubMedGoogle Scholar
  • 25 Firth J, Siddiqi N, Koyanagi A. et al. The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019; 6: 675-712
    CrossrefPubMedGoogle Scholar
  • 26 Day JC, Bentall RP, Roberts C. et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717-724
    CrossrefPubMedGoogle Scholar
  • 27 McCabe R, Healey PG, Priebe S. et al. Shared understanding in psychiatrist-patient communication: Association with treatment adherence in schizophrenia. Patient Educ Couns 2013; 93: 73-79
    CrossrefPubMedGoogle Scholar
  • 28 Correll CU, Kim E, Sliwa JK. et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview. CNS Drugs 2021; 35: 39-59
    CrossrefPubMedGoogle Scholar
  • 29 Bertolini F, Ostuzzi G, Pievani M. et al. Comparing long-acting antipsychotic discontinuation rates under ordinary clinical circumstances: A survival analysis from an observational, pragmatic study. CNS Drugs 2021; 35: 655-665
    CrossrefPubMedGoogle Scholar
  • 30 Peuskens J, Olivares JM, Pecenak J. et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26: 501-509
    CrossrefPubMedGoogle Scholar
  • 31 Acosta FJ, Hernández JL, Pereira J. et al. Medication adherence in schizophrenia. World J Psychiatry 2012; 2: 74-82
    CrossrefPubMedGoogle Scholar
  • 32 von Elm E, Altman DG, Egger M. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349
    CrossrefPubMedGoogle Scholar
  • 33 World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194
    Google Scholar
  • 34 Ostuzzi G, Mazzi MA, Terlizzi S. et al. Factors associated with first-versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One 2018; 13: e0201371
    CrossrefPubMedGoogle Scholar
  • 35 Barbui C, Bertolini F, Bartoli F. et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: Findings from the STAR Network Depot Study. Ther Adv Psychopharmacol 2020; 10: 2045125320978102
    CrossrefPubMedGoogle Scholar
  • 36 Bartoli F, Ostuzzi G, Crocamo C. et al. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: Findings from the STAR Network Depot Study. Int Clin Psychopharmacol 2020; 35: 214-220
    CrossrefPubMedGoogle Scholar
  • 37 Aguglia A, Fusar-Poli L, Amerio A. et al. The Role of attitudes toward medication and treatment adherence in the clinical response to LAIs: Findings from the STAR Network Depot Study. Front Psychiatry 2021; 12: 784366
    CrossrefPubMedGoogle Scholar
  • 38 Bartoli F, Cavaleri D, Callovini T. et al. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. Psychiatry Res 2022; 309: 114405
    CrossrefPubMedGoogle Scholar
  • 39 Kemp R, Hayward P, Applewhaite G. et al. Compliance therapy in psychotic patients: Randomised controlled trial. BMJ 1996; 312: 345-349
    CrossrefPubMedGoogle Scholar
  • 40 Shafer A. Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 2005; 17: 324-335
    CrossrefPubMedGoogle Scholar
  • 41 Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983; 13: 177-183
    CrossrefPubMedGoogle Scholar
  • 42 Rossi A, Arduini L, De Cataldo S. et al. Subjective response to neuroleptic medication: A validation study of the Italian version of the Drug Attitude Inventory (DAI). Epidemiol Psichiatr Soc 2001; 10: 107-114
    CrossrefPubMedGoogle Scholar
  • 43 Marrero RJ, Fumero A, de Miguel A. et al. Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. Patient Educ Couns 2020; 103: 2116-2131
    CrossrefPubMedGoogle Scholar
  • 44 Wiesjahn M, Jung E, Lamster F. et al. Explaining attitudes and adherence to antipsychotic medication: The development of a process model. Schizophr Res Treatment 2014; 2014: 341545
    CrossrefPubMedGoogle Scholar
  • 45 Soria CG, Velasco CF, Martín LF. et al. Attitude toward medication as a predictor of therapeutic adherence. Importance of psychoeducation on treatment. Eur Psychiatry 2016; 33: S565-S566
    CrossrefPubMedGoogle Scholar
  • 46 Sajatovic M, Levin JB, Ramirez LF. et al. Long-acting injectable antipsychotic medication plus customized adherence enhancement in poor adherence patients with bipolar disorder. Prim Care Companion CNS Disord 2021; 23: 20m02888
    CrossrefPubMedGoogle Scholar
  • 47 Mbwambo J, Kaaya S, Lema I. et al. An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania. BMC Psychiatry 2022; 22: 62 DOI: 10.1186/s12888-022-03695-8.
    CrossrefPubMedGoogle Scholar
  • 48 Kikkert MJ, Schene AH, Koeter MW. et al. Medication adherence in schizophrenia: Exploring patients', carers' and professionals’ views. Schizophr Bull 2006; 32: 786-794
    CrossrefPubMedGoogle Scholar
  • 49 Mintz DL. Teaching the prescriber's role: The psychology of psychopharmacology. Acad Psychiatry 2005; 29: 187-194
    CrossrefPubMedGoogle Scholar
  • 50 Velligan DI, Weiden PJ, Sajatovic M. et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70: 1-46
    CrossrefPubMedGoogle Scholar
  • 51 Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Relat Outcome Meas 2014; 5: 43-62
    CrossrefPubMedGoogle Scholar
  • 52 Rodolico A, Bighelli I, Avanzato C. et al. Family interventions for relapse prevention in schizophrenia: A systematic review and network meta-analysis. Lancet Psychiatry. 2022 S2215-0366(21)00437-5 [Epub ahead of print]
    PubMedGoogle Scholar